Investor Presentaiton

107 Investor presentation Full year 2022 Novo NordiskⓇ Potential first human dose with cell therapy in collaboration with Heartseed and others Utilise internal capabilities and disease understanding for stem cell development Accelerate innovation through partnerships Internal capabilities GMP-grade production capability my Academic collaborations Ethical stem cell practices IP positions on differentiation protocols Therapeutic areas Heartseed . iPSC derived cardiomyocyte spheroids for direct injection into heart Parkinson's disease Chronic heart failure LUND 2 first human dose projects upcoming UNIVERSITY Type 1 diabetes BioLamina REVOLUTIONIZING CELL CULTURE Dry age-related macular degeneration UCSF University of California San Francisco • • hESC derived dopaminergic progenitor neurons for placing into the brain Parkinson's disease Novo Nordisk scientists embedded at UCSF lab Process development, manufacturing, QA/QC, facilities and operations at Fremont site GMP: Good manufacturing practice; IP: Intellectual property; iPSC: induced pluripotent stem cells; QA/QC: Combination of quality assurance with quality assurance and quality control; hESC: Human embryonic stem cell

View entire presentation